| Prev Close | 202.66 |
| Day Low/High | 201.42 / 209.25 |
| 52 Wk Low/High | 184.50 / 256.80 |
| Avg Volume | 2.07M |
| Exchange | NYSE |
| Shares Outstanding | 334.31M |
| Market Cap | 67.75B |
| EPS | 38.20 |
| P/E Ratio | N/A |
| Div & Yield | 2.80 (1.40%) |
Concern over weak iPhone 8 launch is overblown and creating an entry point.
An update on the price action, fundamentals and recent news of a number of portfolio stocks.
Concerns about watch, new iPhone aren't putting us off the stock.
Senator tells Jim Cramer the Federal Reserve should 'step up' and show Americans that it will not stand for companies that defraud consumers.
Michael Neidorff, chairman and CEO of Centene, tells Jim Cramer that the Fidelis merger gives his company scale in the largest states.
Marc Lautenbach, president and CEO of Pitney Bowes, tells Jim Cramer his company is removing complexity from shipping for ecommerce applications in the cloud.
Jim Cramer is bullish on Healthcare Trust of America and Marathon Petroleum. But he's cautious about The Trade Desk and CyberArk Software.
Jim Cramer sees a lot of questionable results after the bell, but the enthusiasm -- and the rally -- just keep going every day.
Doug Kass shares his thoughts on some key stocks and reviews some equities.
Patent lawyers are intrigued and competitors will likely challenge, but the move to transfer ownership of the patent to the Saint Regis Mohawk tribe could cause other companies to try a similar tack.
The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.
Hurricane Irma damage is less than expected, which lifts markets. In the portfolio, we add to one position while updating the ratings on two others.
Approval Based on Totality of Evidence From Global Development Program Showing MVASI™ is Highly Similar to Avastin® (bevacizumab)
Best-in-Class Program with More Than Three Million Members Updated For More Rewarding User Experience Through New Digital Platform
Jim Cramer says it's a very rare moment when the absence of negatives, however fleeting or relative, creates a stampede of buying.
Jim Cramer is bullish on Allergan, USG Corp, and Arena Pharmaceuticals.
Here's what you need to know now for Monday, September 11.
Doug Kass shares his thoughts on Goldman Sachs as well as running through some of his takeaways and observations.
Doug Kass shares his thoughts on Comcast, Apple, Disney and a few other companies.
Study Between ABP 980 and Trastuzumab in Patients With HER2-Positive Early Breast Cancer Adds to the Totality of Evidence of Biosimilarity
Markets keep an eye on the storms while the Fed has a surprise. We add a name to the portfolio.
The drugmaker unveiled an agreement that transfers patents for Restasis, Allergan's longstanding dry eye medication, to the Saint Regis Mohawk Tribe, which claims immunity from patent challenges.
T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.
